Dynamic Technology Lab Private Ltd Increases Stake in Novo Nordisk A/S (NYSE:NVO)

Dynamic Technology Lab Private Ltd increased its position in shares of Novo Nordisk A/S (NYSE:NVO) by 42.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 19,346 shares of the company’s stock after purchasing an additional 5,795 shares during the period. Dynamic Technology Lab Private Ltd’s holdings in Novo Nordisk A/S were worth $1,664,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Center for Financial Planning Inc. raised its holdings in shares of Novo Nordisk A/S by 72.4% in the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company’s stock worth $25,000 after buying an additional 123 shares during the period. Dunhill Financial LLC grew its position in Novo Nordisk A/S by 196.8% in the 3rd quarter. Dunhill Financial LLC now owns 469 shares of the company’s stock valued at $56,000 after acquiring an additional 311 shares during the last quarter. Albion Financial Group UT increased its stake in Novo Nordisk A/S by 121.4% in the fourth quarter. Albion Financial Group UT now owns 507 shares of the company’s stock worth $44,000 after purchasing an additional 278 shares during the period. Hager Investment Management Services LLC bought a new stake in shares of Novo Nordisk A/S during the fourth quarter worth $46,000. Finally, Sound Income Strategies LLC boosted its stake in shares of Novo Nordisk A/S by 82.1% during the fourth quarter. Sound Income Strategies LLC now owns 539 shares of the company’s stock valued at $46,000 after purchasing an additional 243 shares during the period. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Stock Down 6.7 %

Shares of NYSE NVO opened at $62.58 on Friday. Novo Nordisk A/S has a 12-month low of $62.37 and a 12-month high of $148.15. The stock’s fifty day simple moving average is $80.85 and its two-hundred day simple moving average is $96.75. The stock has a market capitalization of $280.84 billion, a PE ratio of 19.02, a price-to-earnings-growth ratio of 0.90 and a beta of 0.61. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. As a group, analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The company also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be given a dividend of $0.7874 per share. This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date is Monday, March 31st. This represents a yield of 1.2%. Novo Nordisk A/S’s dividend payout ratio is presently 47.72%.

Analyst Upgrades and Downgrades

NVO has been the topic of several recent analyst reports. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. BMO Capital Markets reduced their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. Morgan Stanley initiated coverage on Novo Nordisk A/S in a report on Wednesday, February 12th. They issued an “equal weight” rating for the company. StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Friday, March 21st. Finally, UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. Three research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $145.25.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.